70
Views
0
CrossRef citations to date
0
Altmetric
Original Research

Comparative analysis of US real-world dosing patterns and direct infusion-related costs for matched cohorts of rheumatoid arthritis patients treated with infliximab or intravenous golimumab

, , , , , & show all
Pages 99-110 | Published online: 15 Jan 2019

Figures & data

Figure 1 Subject selection.

Note: aIndex date is the first GLM-IV or IFX claim after January 1, 2014. bPatients may not have had their index medication within 12 months pre-index; however, they may have received the non-index drug during the pre-index period. In addition, patients could have no claims for a second non-study biologic on the index date.
Abbreviations: GLM-IV, golimumab intravenous; IFX, infliximab; RA, rheumatoid arthritis.
Figure 1 Subject selection.

Table 1 Demographic characteristics of patients prior to matching

Table 2 Clinical characteristics of patients prior to matching

Table 3 Demographic characteristics of matched patients

Table 4 Clinical characteristics of matched patients

Table 5 Treatment patterns and infusion patterns

Figure 2 Distribution of maintenance infusions.

Notes: aAll differences between cohorts for the proportions of maintenance infusions are significant at P<0.001. When maintenance infusion intervals exceeded 9 weeks, the average infusion interval waŝ12 weeks for both IFX and GLM-IV cohorts.
Abbreviations: GLM-IV, golimumab intravenous; IFX, infliximab.
Figure 2 Distribution of maintenance infusions.

Table 6 Drug and infusion expenditures

Figure 3 First-year costs of GLM-IV and IFX therapy comparing recommended dosing intervals and real-world dosing intervals in commercially insured patients.

Abbreviations: GLM-IV, golimumab intravenous; IFX, infliximab.
Figure 3 First-year costs of GLM-IV and IFX therapy comparing recommended dosing intervals and real-world dosing intervals in commercially insured patients.